Cookson Peirce & Co’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.7M | Sell |
16,449
-45,160
| -73% | -$46.1M | 0.65% | 43 |
|
|
2026
Q1 | $56.7M | Buy |
61,609
+39,621
| +180% | +$40.2M | 2.4% | 6 |
|
|
2025
Q4 | $23.6M | Buy |
21,988
+7,011
| +47% | +$6.7M | 0.98% | 31 |
|
|
2025
Q3 | $11.4M | Buy |
14,977
+144
| +1% | +$107K | 0.47% | 55 |
|
|
2025
Q2 | $11.6M | Buy |
14,833
+575
| +4% | +$447K | 0.51% | 59 |
|
|
2025
Q1 | $11.8M | Buy |
14,258
+2,100
| +17% | +$1.75M | 0.59% | 52 |
|
|
2024
Q4 | $9.39M | Buy |
12,158
+560
| +5% | +$464K | 0.43% | 64 |
|
|
2024
Q3 | $10.3M | Sell |
11,598
-10,548
| -48% | -$9.48M | 0.48% | 56 |
|
|
2024
Q2 | $20.1M | Buy |
22,146
+21,526
| +3,472% | +$17.2M | 0.96% | 37 |
|
|
2024
Q1 | $483K | Sell |
620
-30
| -5% | -$21.4K | 0.03% | 162 |
|
|
2023
Q4 | $379K | Sell |
650
-242
| -27% | -$141K | 0.02% | 168 |
|
|
2023
Q3 | $479K | Hold |
892
| – | – | 0.03% | 145 |
|
|
2023
Q2 | $418K | Buy |
892
+47
| +6% | +$19.7K | 0.03% | 156 |
|
|
2023
Q1 | $290K | Sell |
845
-1,780
| -68% | -$600K | 0.02% | 176 |
|
|
2022
Q4 | $961K | Buy |
2,625
+415
| +19% | +$147K | 0.06% | 105 |
|
|
2022
Q3 | $715K | Buy |
2,210
+103
| +5% | +$32.6K | 0.05% | 115 |
|
|
2022
Q2 | $683K | Buy |
2,107
+237
| +13% | +$71.1K | 0.05% | 121 |
|
|
2022
Q1 | $536K | Buy |
1,870
+297
| +19% | +$76.4K | 0.03% | 139 |
|
|
2021
Q4 | $434K | Buy |
+1,573
| New | +$399K | 0.02% | 145 |
|
|
2021
Q2 | – | Sell |
-14,720
| Closed | -$2.75M | – | 215 |
|
|
2021
Q1 | $2.75M | Buy |
+14,720
| New | +$2.88M | 0.18% | 76 |
|
|
2020
Q4 | – | Sell |
-284,273
| Closed | -$42.1M | – | 174 |
|
|
2020
Q3 | $42.1M | Buy |
284,273
+38,849
| +16% | +$6.01M | 3.16% | 8 |
|
|
2020
Q2 | $40.3M | Sell |
245,424
-2,897
| -1% | -$445K | 3.79% | 5 |
|
|
2020
Q1 | $34.4M | Buy |
+248,321
| New | +$34.1M | 3.96% | 1 |
|
|
2019
Q3 | – | Sell |
-2,622
| Closed | -$290K | – | 150 |
|
|
2019
Q2 | $290K | Buy |
2,622
+885
| +51% | +$104K | 0.02% | 138 |
|
|
2019
Q1 | $225K | Buy |
+1,737
| New | +$211K | 0.02% | 140 |
|
|
2015
Q4 | – | Sell |
-4,850
| Closed | -$406K | – | 151 |
|
|
2015
Q3 | $406K | Buy |
4,850
+200
| +4% | +$16.9K | 0.07% | 110 |
|
|
2015
Q2 | $388K | Buy |
4,650
+428
| +10% | +$32.6K | 0.06% | 105 |
|
|
2015
Q1 | $307K | Hold |
4,222
| – | – | 0.05% | 112 |
|
|
2014
Q4 | $291K | Hold |
4,222
| – | – | 0.06% | 109 |
|
|
2014
Q3 | $274K | Buy |
+4,222
| New | +$267K | 0.06% | 111 |
|
Other funds holding LLY
SC
ONB
GIM
Cookson Peirce & Co's LLY Position: Q2 2026 in Review
Cookson Peirce & Co reduced its Eli Lilly (LLY) stake by 73% in Q2 2026, selling an estimated $46.1M and leaving 16,449 shares worth $19.7M. The position accounts for 0.65% of the portfolio, ranked #43.
Cookson Peirce & Co first reported a position in LLY in Q3 2014 and has held it in 30 quarters since. The position peaked at $56.7M in Q1 2026. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Cookson Peirce & Co held 16,449 shares of Eli Lilly worth $19.7M as of Q2 2026.
- Cookson Peirce & Co sold 45,160 Eli Lilly shares in Q2 2026, an estimated $46.1M.
- Eli Lilly made up 0.65% of Cookson Peirce & Co's portfolio in Q2 2026, its #43 holding.
- Cookson Peirce & Co first reported a position in Eli Lilly in Q3 2014 and has held it in 30 quarters since.
- Cookson Peirce & Co's Eli Lilly position peaked at $56.7M in Q1 2026.
- 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Cookson Peirce & Co's 13F filing for Q2 2026, filed 23 Jul 2026.